Advancing process development for antibody-drug conjugates - Incorporation of high-throughput, analytical, and digital tools
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Karlsruhe, Karlsruher Institut für Technologie (KIT), Dissertation, 2020
- Keyword
-
Tools
Antibody-drug conjugates
Incorporation
- Event
-
Veröffentlichung
- (where)
-
Karlsruhe
- (who)
-
KIT-Bibliothek
- (when)
-
2020
- Creator
- Contributor
-
Hubbuch, J.
- DOI
-
10.5445/IR/1000120055
- URN
-
urn:nbn:de:101:1-2020062404595556113929
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Andris, Sebastian
- Hubbuch, J.
- KIT-Bibliothek
Time of origin
- 2020
Other Objects (12)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates